

CURRICULUM VITAE

Date of preparation: June 17, 2022

Neil Vasan, MD, PhD

1130 St. Nicholas Avenue, Room 321A
 Irving Cancer Research Center
 Columbia University School of Medicine
 New York, NY 10032
nv2379@cumc.columbia.edu

Place of Birth: Washington DC
 Citizenship: USA

ACADEMIC APPOINTMENTS, HOSPITAL APPOINTMENTS, AND OTHER WORK EXPERIENCE**Academic Appointments**

| | | |
|-------------------|--|--------------|
| 07/2021 – present | Columbia University College of Physicians & Surgeons Assistant Professor of Medicine | New York, NY |
| 07/2018 – 06/2021 | Weill Cornell Medical College Instructor in Medicine | New York, NY |

Hospital Appointments

| | | |
|-------------------|---|--------------|
| 07/2021 – present | New York-Presbyterian Hospital / Columbia University Irving Medical Center | New York, NY |
| 07/2018 – 06/2021 | Memorial Sloan Kettering Cancer Center Assistant Attending Physician, Breast Medicine Service | New York, NY |

EDUCATION

| | | |
|-------------------|--|---------------|
| 09/2005 – 06/2013 | Yale University School of Medicine MD/PhD, May 2004 <i>PhD in Cell Biology, Structural studies of the GARP tethering complex (2011), Advisor: Karin Reinisch, PhD</i> | New Haven, CT |
| 08/1995 – 05/1999 | Harvard University and Harvard College AB/AM in Chemistry, May 2005 | Cambridge, MA |

TRAINING

| | | |
|-------------------|--|--------------|
| 09/2019 – 06/2021 | Meyer Cancer Center, Weill Cornell Medical College Postdoctoral Fellow, Laboratory of Lewis Cantley, PhD | New York, NY |
| 07/2016 – 08/2019 | Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center Postdoctoral Fellow, Laboratories of José Baselga, MD, PhD and Maurizio Scaltriti, PhD | New York, NY |
| 07/2016 – 06/2017 | Department of Medicine, Memorial Sloan Kettering Cancer Center Medical Oncology Chief Fellow | New York, NY |
| 07/2015 – 06/2018 | Department of Medicine, Memorial Sloan Kettering Cancer Center Medical Oncology Fellow | New York, NY |
| 07/2014 – 06/2015 | Department of Medicine, Massachusetts General Hospital Internal Medicine Resident | Boston, MA |
| 07/2013 – 06/2014 | Department of Medicine, Massachusetts General Hospital Internal Medicine Intern | Boston, MA |

EXPLANATION OF GAPS IN WORK/TRAINING/EDUCATION

Not applicable

LICENSURE AND BOARD CERTIFICATION

LICENSURE

2015 – present New York State Medical License Number 281568-1

BOARD QUALIFICATION

2018 – present Medical Oncology, American Board of Internal Medicine

2017 – present Internal Medicine, American Board of Internal Medicine

HONORS AND AWARDS

| | |
|------|---|
| 2022 | Louis V. Gerstner Jr. Scholar |
| 2022 | ASCI Young Physician-Scientist Award |
| 2022 | New York Super Doctors Rising Star 2022 |
| 2020 | American Association of Cancer Research NextGen Star (8-12 recipients yearly) |
| 2020 | FDA-AACR Oncology Educational Fellowship (20 recipients yearly) |
| 2017 | Society for Translational Oncology Fellows' Forum |
| 2016 | AACR Molecular Biology in Clinical Oncology Workshop |

| | |
|-------------|--|
| 2016 | John Mendelsohn Housestaff Teaching Award, MSKCC |
| 2010 – 2012 | Associate Faculty Member, Faculty of 1000 |
| 2001 – 2005 | Harvard College Scholarship and Dean's List |
| 2001 – 2005 | Robert C. Byrd Scholarship |
| 2001 – 2005 | National Merit Scholar |
| 2001 | United State Presidential Scholar (given to top male high school graduate in WV) |
| 2001 | Eagle Scout |

ACADEMIC SERVICE

| | |
|-------------------|--|
| 01/2022 – present | Columbia Center for Precision Cancer Medicine Monthly Molecular Therapeutics Meeting moderator |
| 05/2020 – present | PI3K Disease Modeling and Drug Targeting Worldwide Zoom Seminar Co-organizer. <i>This is an international biweekly series that I co-organize to promote early career researchers in the PI3K field</i> |
| 09/2020 – 06/2021 | Memorial Sloan Kettering Cancer Center (MSKCC) Grand Rounds Organizing Committee Member |
| 06/2019 – 11/2020 | MSKCC Junior Faculty Council member |

PROFESSIONAL ORGANIZATIONS AND SOCIETIES

- MEMBERSHIPS AND POSITIONS

| | |
|-------------------|---|
| 06/2021 | ASCO Medical Student & Resident Abstract Forum facilitator |
| 03/2021 – present | SWOG Breast Cancer Translational Medicine Working Group member |
| 06/2019 – present | American Society for Clinical Oncology (ASCO) Membership Advisory Committee Early Career Working Group member |
| 06/2018 – present | ASCO Virtual Mentoring Program member |
| 06/2017 – 05/2018 | ASCO University Review Panel member |
| 06/2017 – 05/2018 | ASCO Ethics Committee liaison |
| 04/2016 – 03/2019 | American Association for Cancer Research (AACR) Associate Member Council member |
| 06/2016 – 05/2018 | ASCO Trainee Council member |
| 2019 – present | European Society of Medical Oncology |
| 2015 – present | American Association for Cancer Research |
| 2014 – present | American Society of Clinical Oncology |
| 2008 – 2011 | American Society for Cell Biology |
| 2005 – 2013 | American College of Physicians |

- CONSULTATIVE (FEDERAL, STATE, PRIVATE)

| | |
|-------------|---|
| 2022 – 2026 | Oncology Drugs Advisory Committee (ODAC) standing member (federal) |
| 2022 | Conquer Cancer-BCRF Young Investigator Award (YIA) & Career Development Award (CDA) for Diversity and Inclusion in Breast Cancer Research Expert Review |

Panel member (private)

2020 – present Cancer Prevention & Research Institute of Texas (CPRIT) Product Development Review Council member (state)

2020 – present Innovation in Cancer Informatics (ICI) Grant Review Committee member (private)

- JOURNAL REVIEWER

Breast Cancer Research

Cancer

Cancer Discovery

Cell Death and Differentiation

Clinical Breast Cancer

Hematology/Oncology and Stem Cell Therapy

Journal of Clinical Investigation

Journal of Clinical Investigation Insight

Nature Communications

Oncogene

Science Advances

- EDITORIAL

2022 Peer reviewer for ESMO Handbook of Targeted Therapies and Precision Oncology

2022 Peer reviewer for ASCO Educational Book

2022 Member of ASCO SEP Item Writing Task Force

FELLOWSHIP AND GRANT SUPPORT

- PRESENT SUPPORT

07/2022 – 06/2025 Louis V. Gerstner Jr. Scholar

Amount: \$450,000

Role: Principal Investigator

07/2020 – 06/2025 NCI K08 CA245192

Investigating a hierarchical model for PI3K activation and inhibition in breast cancer by double *PIK3CA* mutations in *cis*

Amount: \$1,315,170

Role: Principal Investigator

10/2019 – 07/2022 Susan G. Komen Career Catalyst Research (CCR) Grant GC235789

Double hit compound PIK3CA mutations in ER+ metastatic breast cancer

Amount: \$450,000

Role: Principal Investigator

- PAST SUPPORT

07/2020 – 06/2021 NCI P50 CA247749

MSK SPORE in Genomic Instability in Breast Cancer (Developmental Research Program)

Amount: \$50,000 yearly

Role: Co-Investigator

PI: Simon Powell and Jorge Reis Filho

08/2018 – 07/2020 NCI R21 CA223789

Mechanisms of action dual compound oncogenic PIK3CA mutations

Amount: \$105,487

Role: Co-Investigator

PI: Maurizio Scaltriti

07/2018 – 06/2019 American Society of Clinical Oncology Young Investigator Award

Dual compound PIK3CA mutations in the pathogenesis and treatment of metastatic breast cancer

Amount: \$50,000

Role: Principal Investigator

07/2018 – 06/2019 Society of Memorial Sloan Kettering Research Grant

Discovery and Validation of Tandem Mutations Driving Cancer

Amount: \$50,000

Role: Principal Investigator

06/2018 – 06/2020 Innovations in Cancer Informatics Grant, Brown Performance Group GC240757

Discovery and Validation of Tandem Mutations Driving Cancer

Amount:

Role: Principal Investigator

09/2017 – 08/2018 NIH T32-CA009207

Investigational Cancer Therapeutics Training Program Grant (ICTTP)

Role: Trainee

PI: Mark Kris and Jedd Wolchok

09/2016 – 06/2017 NIH UL1TR00457

Clinical Research Methodology Curriculum (CRMC)

Role: Participant

PI: Dean Bajorin

09/2009 – 08/2012 NIH F30-HL097628-01

Structural Studies of the Exocyst

Role: Principal Investigator

07/2006 – 06/2013 NIH MSTP TG 2T32GM07205

Medical Scientist Training Program (MSTP)

Role: Trainee

PI: James Jamieson

- PENDING SUPPORT

None

EDUCATIONAL CONTRIBUTIONS

- Direct Teaching/Precepting/Supervising

10/2021 Teaching Columbia University Vagelos College of Physicians and Surgeons (VP&S) medical students, Oncology small group sessions, 2 days/year (3 hours total)

03/2021 – present Teaching Columbia University Medical Center (CUMC) fellows, ad hoc basis

07/2018 – 06/2021 Teaching Memorial Sloan Kettering Cancer Center (MSKCC) residents as Ward attending, 2 weeks/year

07/2018 – 06/2021 Teaching MSKCC residents and fellows in Outpatient clinic, ad hoc basis

07/2015 – present Teaching MSKCC residents and fellows in weekly noon conferences, ad hoc basis

- Development of instructional material and curriculum used locally
None

- Advising and Mentorship

05/2022 – present Member of thesis committee of Jessica Armand (lab of Hee Won Yang)

01/2022 – present Direct laboratory training and supervising of Allison Kearney (postdoctoral fellow)

10/2021 – present Direct laboratory training and supervising of Hanna Karvonen (postdoctoral fellow)

10/2021 – present Direct laboratory training and supervising of Sophie Abrahamson (Columbia undergraduate student)

10/2021 – present Direct laboratory training and supervising of Maya Schonberg (high school student)

05/2020 – present Direct laboratory training and supervising of Ruchita Rathod (laboratory technician)

06/2017 – 08/2019 Direct laboratory training and supervising of Hong Zhao (laboratory technician, currently laboratory technician). She was a second author on my postdoctoral *Science* paper.

06/2018 – present Direct laboratory training and supervising of Abiha Kazmi (high school student, currently undergraduate student), as a Stand Up to Cancer Emperor Science Award Mentor. She was a co-author on my 2019 *Science* paper and received the Goldwater Scholarship.

- Educational Administration and Leadership

11/2021 – present Interviewer for Columbia MSTP program

- Instructional/Educational Materials used in Print or other Media

10/2021 – present Expert reviewer for breast cancer content on www.survivornet.com, ad hoc basis

- Community Education

10/2021 Bone Metastases. Susan G. Komen Foundation Metastatic Breast Cancer Awareness Day 2021. 30-minute presentation for breast cancer survivors.

10/2021 Essentials in Cardio-Oncology: Anthracycline and HER-2 Targeted Therapy Related Cardiotoxicity. New York-Presbyterian/CUIMC Cardio-Oncology Summit 2021. One hour presentation for cardiologists.

- 10/2019 Advances in Lobular Breast Cancer. New York Metastatic Breast Cancer Conference, New York, NY. One hour presentation for breast cancer survivors.
- 4/2019 Advances in Hormone Receptor Positive Breast Cancer. Living Beyond Breast Cancer 2019 Conference on Metastatic Breast Cancer, Philadelphia, PA. One hour presentation for breast cancer survivors.

REPORT OF CLINICAL AND PUBLIC HEALTH ACTIVITIES AND INNOVATIONS

- 02/2022 – present Inpatient Ward attending for Columbia University Medical Center (CUMC) Oncology Service, 4 weeks/year
- 09/2021 – present Outpatient medical oncologist with CUMC Breast Oncology group, ½ day weekly
- 07/2018 – 06/2021 Inpatient Ward attending for Memorial Sloan Kettering Cancer Center (MSKCC) Breast Medicine Service, 2 weeks/year
- 07/2018 – 06/2021 Outpatient medical oncologist on MSKCC Breast Medicine Service, ½ day weekly

PATENTS & INVENTIONS

- Patents

Vasan N, Baselga J. U.S. Patent Number WO2020041684A1: “Biomarkers for Determining Responsiveness of a Cancer to PI3K Inhibitors,” Patent granted February 27, 2020.

PUBLICATIONS

- ORIGINAL, PEER-REVIEWED RESEARCH PUBLICATIONS IN PRINT OR OTHER MEDIA

Taylor SR, Ramsamooj S, Liang RJ, Katti A, Pozovskiy R, **Vasan N**, Hwang SK, Nahiyaan N, Francoeur NJ, Schatoff EM, Johnson JL, Shah MA, Dannenberg AJ, Sebra RP, Dow LE, Cantley LC, Kyu KY, Goncalves MD. Dietary fructose improves intestinal cell survival and nutrient absorption. *Nature* 2021 597:263-267.

Li J, Duran MA, Dhanota N, Chatila WK, Kwon J, Sriram RK, Humphries MP, Salto-Tellez M, James JA, Hanna MG, Melms JC, Vallabhaneni S, Litchfield K, Martin ML, Dorsaint P, Cavallo JA, Li P, Pauli C, Gottesdiener L, DiPardo BJ, Hollmann TJ, Merghoub T, Wen HY, Reis-Filho JS, Riaz N, Dr. Kalbasi A, **Vasan N**, Wolchok JD, Elemento O, Swanton C, Shoushtari AN, Bettigole SE, Powell SN, Usaite I, Biswas D, Li HW, Su SM, Bareja R, Parkes EE, Izar B, Bakhoum S. Metastasis and immune evasion from extracellular cGAMP hydrolysis. *Cancer Discov*, 2021 11:1212-1227.

Cocco E, Lee JE, Kannan S, Schram AM, Won HH, Shifman S, Kulick A, Baldino L, Toska E, Arruabarrena-Aristorena A, Kittane S, Wu F, Cai Y, Arena S, Mussolin B, Kannan R, **Vasan N**, Gorelick AN, Berger MF, Novoplansky O, Jagadeeshan S, Liao Y, Rix U, Misale S, Taylor BS, Bardelli A, Hechtman JF, Hyman DM, Elkabets M, de Stanchina E, Verma CS, Ventura A, Drilon A, Scaltriti M. TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors. *Cancer Discov* 2020 11:126-141.

Gorelick A, Sanchez-Rivera F, Cai Y, Bielski C, Biederstedt E, Jonsson P, Richards A, **Vasan N**, Penson A, Friedman N, Ho YJ, Baslan T, Bandlamudi C, Scaltriti M, Schultz N, Lowe S, Reznik E,

Taylor B. Phase and context shape the function of composite oncogenic mutations. *Nature* 2020

Razavi P, Dickler MN, Shah PD, Toy W, Brown DN, Won HH, Li BT, Shen R, **Vasani N**, Modi S, Jhaveri K, Caravella BA, Patil S, Selenica P, Zamora S, Cowan AM, Comen E, Singh A, Covey A, Berger MF, Hudis CA, Norton L, Nagy RJ, Odegaard JI, Lanman RB, Solit DB, Robson ME, Lacouture ME, Brogi E, Reis-Filho JS, Moynahan ME, Scaltriti M, Chandarlapaty S. Alterations in *PTEN* and *ESR1* promote clinical resistance to alpelisib plus aromatase inhibitors. *Nat Cancer* 2020 1:382-393.

Vasani N, Razavi P, Johnson JL, Shao H, Shah H, Antoine A, Ladewig E, Gorelick A, Lin TY, Toska E, Xu G, Kazmi A, Chang MT, Taylor BS, Dickler MN, Jhaveri K, Chandarlapaty S, Rabadan R, Reznik E, Smith ML, Sebra R, Schimmoller F, Wilson TR, Friedman LS, Cantley LC, Scaltriti M*, Baselga J*. Double *PIK3CA* mutations in *cis* increase oncogenicity and sensitivity to PI3K α inhibitors. *Science* 2019 366:714-723.

Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, **Vasani N**, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, Cheng ML, Zehir A, Kandath C, Patel R, Huberman K, Smyth LM, Jhaveri K, Modi S, Traina TA, Dang C, Zhang W, Weigelt B, Li BT, Ladanyi M, Hyman DM, Schultz N, Robson ME, Hudis C, Brogi E, Viale A, Norton L, Dickler MN, Berger MF, Iacobuzio-Donahue CA, Chandarlapaty S, Scaltriti M, Reis-Filho JS, Solit DB*, Taylor BS*, Baselga J*. The genomic landscape of endocrine resistant advanced breast cancers. *Cancer Cell* 2018 34:427-438.

Vasani N, Yelensky R, Wang K, Moulder S, Dzimitrowicz H, Avritscher R, Wang B, Wu Y, Cronin MT, Palmer G, Symmans WF, Miller VA, Stephens P, Puztai L. A Targeted Next Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice. *Oncologist* 2014 19:453-458.

Vasani N, Hutagalung A, Novick P, and Reinisch KM. Structure of a C-terminal fragment of its Vps53 subunit suggests similarity of the Golgi-associated retrograde protein (GARP) complex to a family of tethering complexes. *PNAS* 2010 107:14176-81.

- OTHER PEER-REVIEWED PUBLICATIONS IN PRINT OR OTHER MEDIA

None

- REVIEWS, CHAPTERS, MONOGRAPHS, EDITORIALS

Vasani N and Cantley LC. At a crossroad: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy. *Nat Rev Clin Oncol* 2022, in press.

Mullangi S and **Vasani N**. Genomic Characterization of De Novo Metastatic Breast Cancer. *Clin Breast Cancer* 2022 22:98-102.

Castel P, Toska E, **Vasani N**, Cocco E, Scaltriti M. José Baselga (1959-2021). *Cancer Cell* 2021 39:581-582.

Vasani N, Hyman DM, and Baselga, J. A view on drug resistance in cancer. *Nature* 2019 575:299-309.

Vasani N*, Toska E*, Scaltriti M. Overview of the relevance of PI3K pathway in HR-positive breast cancer. *Ann Oncol* 2019 30:3-11.

Vasani N, Boyer JL, and Herbst RS. A Ras renaissance: emerging targeted therapies for KRas-mutated non-small cell lung cancer. *Clin Cancer Res* 2014 20:3921-3930.

- BOOKS/TEXTBOOKS FOR MEDICAL OR SCIENTIFIC COMMUNITY

Vasani N*, Carlo M*, Drilon A, Postow M. Pocket Oncology, 2nd edition. Lippincott, Williams, & Wilkins, 2018. Editor and Author.

Bhushan V, Le T, **Vasani N**, Tolles J. First Aid for the USMLE Step 1 2010. McGraw-Hill Company, 2010. Editor.

Bhushan V, Le T, Grimm L, **Vasani N**. First Aid for the USMLE Step 1 2009. McGraw-Hill Company, 2009. Editor.

- MEETINGS/INVITED ORAL AND POSTER PRESENTATIONS

| | |
|---------|---|
| 12/2021 | Genomic landscape of HER2-negative advanced or metastatic breast cancer with PIK3CA gain-of-function mutations. San Antonio Breast Cancer Symposium 2021. Poster presentation. |
| 09/2020 | A pan-cancer analysis of double PIK3CA mutations. ESMO 2020 Virtual Congress. Poster presentation. Abstract published in <i>Annals of Oncology</i> . |
| 06/2020 | Identifying novel ways to overcome or prevent drug resistance. AACR 2020 Virtual Conference. Invited oral presentation. Abstract published in <i>Cancer Research</i> . |
| 06/2020 | Double PIK3CA mutations in cis enhance PI3K α oncogene activation and sensitivity to PI3K α inhibitors in breast cancer. AACR 2020 Virtual Conference. Invited oral presentation. Abstract published in <i>Cancer Research</i> . |
| 12/2019 | Double PIK3CA mutations in cis enhance PI3K α oncogene activation and sensitivity to PI3K α inhibitors in breast cancer. San Antonio Breast Cancer Symposium 2019. San Antonio, TX. Poster presentation. Abstract published in <i>Cancer Research</i> . |
| 05/2019 | Double PIK3CA mutations in cis enhance PI3K α oncogene activation and sensitivity to PI3K α inhibitors in breast cancer. ESMO Breast Cancer 2019. Berlin, Germany. Oral presentation. Abstract published in <i>Annals of Oncology</i> . |
| 04/2019 | Double PIK3CA mutations in cis enhance PI3K oncogene activation and sensitivity to PI3K α inhibitors in breast cancer. AACR Annual Meeting. Atlanta, GA. Poster presentation. Abstract published in <i>Cancer Research</i> . |
| 03/2019 | Double PIK3CA mutations in cis enhance PI3K oncogene activation and sensitivity to PI3K α inhibitors in breast cancer. The Tumour Cell: Plasticity, Progression and Therapy. New York, NY. Poster presentation. |
| 12/2018 | Compound PIK3CA mutations support a mutational dose response model for oncogene activation and response to PI3K inhibitor targeted therapy in breast cancer. AACR Targeting PI3K/mTOR Signaling. Boston, MA. Poster presentation. |

- 06/2017 On the Shoulders of Giants. American Society of Clinical Oncology. Chicago, IL. Invited oral presentation.
- 12/2010 Structure of a C-terminal fragment of its Vps53 subunit suggests similarity of the GARP complex to a family of tethering complexes. American Society for Cell Biology annual meeting, Philadelphia, PA, 2010. Oral presentation.
- 10/2010 Structural studies of the GARP tethering complex. American Society for Biochemistry and Molecular Biology Special Symposium on the Secretory and Endocytic Pathways, Tahoe City, CA, 2010. Poster presentation.
- 07/2010 Structural studies of the GARP tethering complex. National MD/PhD Student Conference, Keystone, CO, 2010. Poster presentation.

- CASE REPORTS

Blow T, Hyde PN, Falcone JN, Neinstein A, **Vasan N**, Chitkara R, Hurd MA, Sardesai S, Lustberg MB, Flory JH, Volek JS, Goncalves MD. Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series. *Integr Cancer Ther* 2021 20: 15347354211032283.

Vasan N, Braghiroli MI, Shoushtari AN, *et al.* An elderly man with remote history of metastatic melanoma now with localized pancreas cancer and new liver masses. *Journal of Gastrointestinal Oncology* 2017 8:596-602.

Vasan N, Saglan O, Killelea BK. Metastatic leiomyosarcoma presenting as bilateral, multifocal breast masses. *BMJ Case Reports* 2012 doi:10.1136/bcr-2012-007188.

- LETTERS TO THE EDITOR

None

- OTHER MEDIA

None

- THESIS

Vasan N. Structural studies of the GARP tethering complex. Yale University School of Medicine, 2011.

- OTHER NON-PEER REVIEWED PUBLICATIONS IN PRINT OR OTHER MEDIA

Vasan N and Dickler MN State-of-the-Art Update: CDK4/6 Inhibitors in ER+ Metastatic Breast Cancer. *AJHO* 2017 13:16-22.

- NON-AUTHORED PUBLICATIONS

My postdoctoral paper (Vasan et al, *Science* 2019) has been featured in the following publications:

- 1) Perspective by Dr. Alex Toker (*Science* 2019, 366:685-686)
- 2) Online Research Watch in *Cancer Discovery* (DOI: 10.1158/2159-8290.CD-RW2019-172)
- 3) News in Depth in *Cancer Discovery* (DOI: 10.1158/2159-8290.CD-ND2020-013)

- 4) In The Literature in *ESMO Open* (DOI: 10.1136/esmooopen-2020-00680)
- 5) Genomeweb.com (www.genomeweb.com/cancer/double-mutations-pik3ca-gene-increase-patient-sensitivity-targeted-therapies-study-finds#.Xp79Wy-z2u5)
- 6) “Your Drug Mileage May Vary: The PIK3CA Double Mutation Story” by Liz Tseng in *Medium* (<https://medium.com/pacbio/your-drug-mileage-may-vary-the-pik3ca-double-mutation-story-83f41f6a4f61>)

The Democratization of Precision Medicine: A Clinician's Perspective on the Future of Oncology Care - Q&A With Neil Vasani, MD, PhD. *AJMC* 2020.

INVITED AND/OR PEER-SELECTED PRESENTATIONS AT REGIONAL, NATIONAL OR INTERNATIONAL LEVELS:

| | |
|---------|---|
| 02/2022 | FDA Oncology Center of Excellence (OCE) Clinical Rounds. Invited speaker. |
| 03/2021 | FDA Oncology Center of Excellence Minisymposium on Emerging Biomarkers in Breast Cancer—Looking Beyond ER, PR, and HER2. Invited organizer and panelist. |
| 10/2020 | Oncogene additivity in the PI3K pathway. 8th Annual Cancer Research and Oncology Virtual Event. Invited speaker. |
| 09/2020 | Oncogene additivity in the PI3K pathway. Women’s Malignancies Branch seminar, National Cancer Institute. Invited seminar speaker. |
| 02/2018 | Targeting Cell Cycle Progression: The latest advances on CDK4/6 inhibition in metastatic breast cancer. Peninsula Regional Medical Center, Salisbury, MD. Invited grand rounds speaker. |
| 01/2018 | Targeting Cell Cycle Progression: The latest advances on CDK4/6 inhibition in metastatic breast cancer. Grand Rounds, Maimonides Cancer Center, Brooklyn, NY. Invited grand rounds speaker. |
| 01/2018 | Targeting Cell Cycle Progression: The latest advances on CDK4/6 inhibition in metastatic breast cancer. Grand Rounds, John Theurer Cancer Center, Hackensack, NJ. Invited grand rounds speaker. |
| 07/2016 | Applying for Fellowship...What Do I Need to Know? <i>NEJM</i> Resident 360. Invited moderator. |
| 06/2016 | Physicians Learning and Teaching in Oncology (PLATO) 5 th Annual Fellows Forum in Breast Oncology. Chicago, IL. Invited speaker. |